Regarding China, it would be nice to know exactly what Edding did with respect to application for national reimbursement. I found a list here: https://www.navlindaily.com/article/24091/china-releases-2024-nrdl-adds-91-drugs and here: https://www.navlindaily.com/article/22875/nhsa-concludes-preliminary-evaluation-for-list-of-drugs-included-in-2024-nrdl which lists all the drugs that passed the initial review, and were allowed to proceed to the formal review stage. Vascepa was not on either list. So, I'm not sure Vascepa was even submitted for this year. And if it was, it was not even considered for approval. This MAY mean that it will be considered for next year. But if it was booted from even initial consideration, then approval next year seems unlikely. Like most things Amarin, it would just be nice to know more information. so that investors can make informed decisions.
Market Data 
Markets 
AI
